Abstract 921P
Background
Incidence of oropharyngeal squamous cell carcinoma (OPSCC) increases due to rise in human papilloma virus (HPV) related cancers. The tumor microenvironment (TME) of HPV+ OPSCC is characterized as more immune tolerant, with higher density of tumor-infiltrating lymphocytes (TILs). The role of tumor-associated macrophages (TAMs) remains unclear. M2-like TAMs are correlated with impaired overall survival (OS) in other tumor types. This study characterizes the prognostic impact of M2-like TAMs in OPSCC.
Methods
Fifty-eight patients with primary OPSCC, undergoing definite treatment (surgery, radiotherapy, chemoradiotherapy or a combination), were included. FFPE samples were stained for P16, TILs (CD3, CD8, FOXP3) and TAMs (CD68, CD163 and CD206) markers. Semi-quantitative assessment of each marker, in the tumor nest(t) and stroma(s), was executed by a board certified pathologist. Survival estimates were calculated via the Kaplan-Meier method using the log-rank test, using the ad hoc calculated cut-off point. Uni- and multivariate analysis were performed via cox proportional hazard model.
Results
The median density of sCD3, sCD8, tCD68 and sCD206 TAMs was higher in P16+, compared to P16–, whereas FOXP3 and CD163 infiltration was similar according to P16 status. In univariate analysis, tumors with high leukocyte infiltrates (sTIL, sCD8, tCD8, sFOXP3, tCD68, sCD206) had a better overall survival (OS), whereas sTIL-high and tCD8-high were the only factors associated with DFS. High tCD68 (HR 0.19) and sCD206 (HR 0.40) were associated with improved OS in P16+ OPSCC, but not in P16-. sCD163 and tCD163 infiltration was not related to adverse outcomes in P16+ nor in P16-. Table: 921P
Clinical and immunohistochemical characteristics
P16- | P16+ | p value | |
N | 39 | 19 | |
mean Age (y, SD) | 58.8y (8.0) | 59.8y (8.8) | 0.65 |
mDFS (months, 95%CI) | 14.4m (7.8-48)* | 158m (30-NR)* | ConclusionsIn this study, high tCD68 and sCD206 expression was associated with a better OS in OPSCC, albeit only in P16+ tumors. No concordance was found between CD163 and CD206 expression and both had a different prognostic impact. This illustrates the complexity of TIL-TAM interplay and the TAM spectrum diversity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyGhent University Hospital. FundingGhent University Hospital Fonds voor Innovatie en Klinisch Onderzoek (FIKO). DisclosureM. Saerens: Financial Interests, Institutional, Invited Speaker: Pierre-Fabre, BMS, MSD; Financial Interests, Institutional, Advisory Board: Novartis, MSD. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest. Resources from the same session1056P - Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital recordsPresenter: Annelies Verbiest Session: Poster session 03 1057P - Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysisPresenter: Simeone D'Ambrosio Session: Poster session 03 1058P - Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequencesPresenter: Damien Bruyat Session: Poster session 03 1059P - Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancersPresenter: Rebecca Romanò Session: Poster session 03 1060P - Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learningPresenter: Song-Bin Guo Session: Poster session 03 1061P - Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic reviewPresenter: Filippo Vitale Session: Poster session 03 1062P - Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapyPresenter: Èlia Sais Session: Poster session 03 1063P - Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohortPresenter: Víctor Albarrán Fernández Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|